Biography and Research Information
OverviewAI-generated summary
Baha’a Jabali's research focuses on the discovery and development of novel kinase inhibitors, particularly for cancer treatment. His work has led to the identification of compounds targeting specific pathways involved in tumor growth and proliferation. He has published research on macrocyclic kinase inhibitors, exploring strategies to limit conformational flexibility for improved targeting of the kinome.
Jabali's recent publications include the discovery of an orally active selective aurora kinase B inhibitor, N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide. He has also investigated pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors. His scholarship metrics include an h-index of 4, with 5 total publications and 104 total citations. Jabali collaborates with researchers at the University of Arkansas for Medical Sciences, including Brendan Frett and Baku Acharya.
Metrics
- h-index: 4
- Publications: 5
- Citations: 109
Selected Publications
-
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)
Collaboration Network
Top Collaborators
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
- Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor
Similar Researchers
Based on overlapping research topics